ARS Pharmaceuticals, Inc. (SPRY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Financial Position: Ended the year with $228.4 million in cash, cash equivalents, and short-term investments. R&D Expenses: Research and development expenses increased to $20.3 million for the year, up from $18.4 million in 2022. G&A Expenses: General and administrative expenses rose to $47.3 million for the year, a significant increase from $18.5 million in the previous year.
Preparing to submit response to the FDA’s CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period In Phase 2 urticaria clinical trial, neffy met primary endpoints and showed rapid symptom control; planning to initiate outpatient study later in 2024, potentially followed by initiation of a single pivotal effica